[go: up one dir, main page]

EP4203987A4 - Compositions et méthodes pour le traitement de la neuro-inflammation oculaire - Google Patents

Compositions et méthodes pour le traitement de la neuro-inflammation oculaire Download PDF

Info

Publication number
EP4203987A4
EP4203987A4 EP21862665.3A EP21862665A EP4203987A4 EP 4203987 A4 EP4203987 A4 EP 4203987A4 EP 21862665 A EP21862665 A EP 21862665A EP 4203987 A4 EP4203987 A4 EP 4203987A4
Authority
EP
European Patent Office
Prior art keywords
eye
compositions
treatment
methods
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21862665.3A
Other languages
German (de)
English (en)
Other versions
EP4203987A2 (fr
Inventor
Yury Miller
Soo-Ho Choi
Wonkyu JU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP4203987A2 publication Critical patent/EP4203987A2/fr
Publication of EP4203987A4 publication Critical patent/EP4203987A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0368—Animal model for inflammation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21862665.3A 2020-08-25 2021-08-25 Compositions et méthodes pour le traitement de la neuro-inflammation oculaire Pending EP4203987A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070145P 2020-08-25 2020-08-25
PCT/US2021/047569 WO2022046919A2 (fr) 2020-08-25 2021-08-25 Compositions et méthodes pour le traitement de la neuro-inflammation oculaire

Publications (2)

Publication Number Publication Date
EP4203987A2 EP4203987A2 (fr) 2023-07-05
EP4203987A4 true EP4203987A4 (fr) 2024-10-16

Family

ID=80353872

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21862665.3A Pending EP4203987A4 (fr) 2020-08-25 2021-08-25 Compositions et méthodes pour le traitement de la neuro-inflammation oculaire

Country Status (3)

Country Link
EP (1) EP4203987A4 (fr)
CA (1) CA3190597A1 (fr)
WO (1) WO2022046919A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022198073A1 (fr) * 2021-03-18 2022-09-22 The Regents Of The University Of California Compositions et procédés permettant de cibler des cellules inflammatoires ou activées et de traiter ou d'améliorer des états inflammatoires et la douleur

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6031718B2 (ja) * 2011-09-20 2016-11-30 国立大学法人 熊本大学 リポ蛋白を用いたα２−マクログロブリンの神経保護抑制効果抑止剤及び眼科用組成物
US10364275B2 (en) * 2013-05-27 2019-07-30 The Regents Of The University Of California Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022198073A1 (fr) * 2021-03-18 2022-09-22 The Regents Of The University Of California Compositions et procédés permettant de cibler des cellules inflammatoires ou activées et de traiter ou d'améliorer des états inflammatoires et la douleur

Also Published As

Publication number Publication date
EP4203987A2 (fr) 2023-07-05
WO2022046919A3 (fr) 2022-04-14
CA3190597A1 (fr) 2022-03-03
WO2022046919A2 (fr) 2022-03-03

Similar Documents

Publication Publication Date Title
EP4415755A4 (fr) Compositions ciblant ace2 et méthodes de traitement de la covid-19
EP3934615A4 (fr) Compositions et méthodes de traitement de l'acné
EP3969597A4 (fr) Compositions et procédés pour le traitement de maladies médiées par l'atpase
EP4204443A4 (fr) Méthodes et compositions pour le traitement du glioblastome
EP4408412A4 (fr) Compositions et procédés de traitement de céphalées
EP4165025A4 (fr) Compositions et méthodes de traitement et de prévention de troubles neurologiques
EP3654964A4 (fr) Composition et méthodes pour le traitement de la myopie
EP3681871A4 (fr) Compositions et procédés pour le traitement d'une lésion cérébrale
EP3986439A4 (fr) Compositions et méthodes utiles dans le traitement de maladies du cerveau
EP3618868A4 (fr) Méthodes et compositions permettant de traiter des maladies oculaires allergiques
EP4337174A4 (fr) Méthodes et compositions pour le traitement d'infections virales
EP4340860A4 (fr) Compositions et méthodes de traitement de la neuropathie
EP4518846A4 (fr) Compositions et méthodes de traitement de l'épilepsie
EP4210755A4 (fr) Compositions et méthodes de traitement de troubles neurologiques
EP3810755A4 (fr) Compositions et méthodes de traitement du vih
EP4429763A4 (fr) Compositions et méthodes pour traiter un saignement et des troubles de saignement
EP4308116A4 (fr) Méthodes et compositions de traitement de maladies oculaires
EP3813794A4 (fr) Compositions ophtalmiques et méthodes de traitement de troubles oculaires
EP4304596A4 (fr) Compositions et méthodes de traitement de la polycythémie
EP4203987A4 (fr) Compositions et méthodes pour le traitement de la neuro-inflammation oculaire
EP4100029A4 (fr) Compositions et procédés pour les utiliser pour le traitement de la mammite
EP3958915A4 (fr) Compositions et méthodes utilisables pour le traitement de l'oeil sec
EP3921286A4 (fr) Procédés et compositions pour le traitement d'eau produite
EP4433076A4 (fr) Compositions et procédés pour le traitement de maladies et de lésions oculaires
EP3823626A4 (fr) Compositions et méthodes de traitement de l'autisme

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230321

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230802

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40095688

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240917

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20240911BHEP

Ipc: A61K 48/00 20060101ALI20240911BHEP

Ipc: A61P 27/02 20060101ALI20240911BHEP

Ipc: A61P 3/06 20060101ALI20240911BHEP

Ipc: A61P 29/00 20060101ALI20240911BHEP

Ipc: A61K 38/17 20060101ALI20240911BHEP

Ipc: A61K 38/00 20060101AFI20240911BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250626